Ajanta Pharma Limited, announced the launch of memantine hydrochloride tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. Memantine hydrochloride is an anti-dementia drug and is a bioequivalent generic version of Namenda.
The company has launched it in 2 strengths 5mg and 10mg tablets to address different levels of treatment.
Memantine hydrochloride tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the United States Food & Drug Administration (FDA) has granted Ajanta Pharma 10 final approvals and 2 tentative approvals for its Abbreviated New Drug Application (ANDA). Additional 14 ANDAs are pending approval from the FDA.